Incentives Versus Defaults: Cost-Effectiveness of Behavioral Approaches for HIV Screening

Zachary Wagner, Juan Carlos C. Montoy, Emmanuel Drabo, William H. Dow

Research output: Contribution to journalArticle

Abstract

Many HIV positive individuals are still undiagnosed, which has led health systems to try many approaches to expand HIV testing. In a randomized controlled trial, we found that behavioral economics interventions (opt-out testing and financial incentives) each improved HIV testing rates and these approaches are being implemented by several hospital systems. However, it is unclear if these strategies are cost-effective. We quantified the cost-effectiveness of different behavioral approaches to HIV screening—opt-out testing, financial incentives, and their combination—in terms of cost per new HIV diagnosis and infections averted. We estimated the incremental number of new HIV diagnoses and program costs using a mathematical screening model, and infections averted using and HIV transmission model. We used a 1-year time horizon and a hospital perspective. Switching from opt-into opt-out results in 39 additional diagnoses (56% increase) after 1-year at a cost of $3807 per new diagnosis. Switching from no incentive to a $1, $5, or $10 incentive adds 14, 13, and 28 new diagnoses (20, 19, and 41% increases) at a cost of $11,050, $17,984, and $15,298 per new diagnosis, respectively. Layering on financial incentives to opt-out testing enhances program effectiveness, though at a greater marginal cost per diagnosis. We found a similar pattern for infections averted. This is one of the first cost-effectiveness analyses of behavioral economics interventions in public health. Changing the choice architecture from opt-into opt-out and giving financial incentives for testing are both cost-effective in terms of detecting HIV and reducing transmission. For hospitals interested in increasing HIV screening rates, changing the choice architecture is an efficient strategy and more efficient than incentives.

Original languageEnglish (US)
JournalAIDS and behavior
DOIs
StatePublished - Jan 1 2019

Fingerprint

Cost-Benefit Analysis
Motivation
HIV
Costs and Cost Analysis
Behavioral Economics
Program Evaluation
Infection
HIV Infections
Theoretical Models
Randomized Controlled Trials
Public Health
Health

Keywords

  • Behavioral economics
  • Cost-effectiveness
  • Defaults
  • HIV testing
  • Incentives

ASJC Scopus subject areas

  • Social Psychology
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

Incentives Versus Defaults : Cost-Effectiveness of Behavioral Approaches for HIV Screening. / Wagner, Zachary; Montoy, Juan Carlos C.; Drabo, Emmanuel; Dow, William H.

In: AIDS and behavior, 01.01.2019.

Research output: Contribution to journalArticle

@article{5378e6b60b3549cf83ee9f65427e294e,
title = "Incentives Versus Defaults: Cost-Effectiveness of Behavioral Approaches for HIV Screening",
abstract = "Many HIV positive individuals are still undiagnosed, which has led health systems to try many approaches to expand HIV testing. In a randomized controlled trial, we found that behavioral economics interventions (opt-out testing and financial incentives) each improved HIV testing rates and these approaches are being implemented by several hospital systems. However, it is unclear if these strategies are cost-effective. We quantified the cost-effectiveness of different behavioral approaches to HIV screening—opt-out testing, financial incentives, and their combination—in terms of cost per new HIV diagnosis and infections averted. We estimated the incremental number of new HIV diagnoses and program costs using a mathematical screening model, and infections averted using and HIV transmission model. We used a 1-year time horizon and a hospital perspective. Switching from opt-into opt-out results in 39 additional diagnoses (56{\%} increase) after 1-year at a cost of $3807 per new diagnosis. Switching from no incentive to a $1, $5, or $10 incentive adds 14, 13, and 28 new diagnoses (20, 19, and 41{\%} increases) at a cost of $11,050, $17,984, and $15,298 per new diagnosis, respectively. Layering on financial incentives to opt-out testing enhances program effectiveness, though at a greater marginal cost per diagnosis. We found a similar pattern for infections averted. This is one of the first cost-effectiveness analyses of behavioral economics interventions in public health. Changing the choice architecture from opt-into opt-out and giving financial incentives for testing are both cost-effective in terms of detecting HIV and reducing transmission. For hospitals interested in increasing HIV screening rates, changing the choice architecture is an efficient strategy and more efficient than incentives.",
keywords = "Behavioral economics, Cost-effectiveness, Defaults, HIV testing, Incentives",
author = "Zachary Wagner and Montoy, {Juan Carlos C.} and Emmanuel Drabo and Dow, {William H.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/s10461-019-02425-8",
language = "English (US)",
journal = "AIDS and Behavior",
issn = "1090-7165",
publisher = "Springer New York",

}

TY - JOUR

T1 - Incentives Versus Defaults

T2 - Cost-Effectiveness of Behavioral Approaches for HIV Screening

AU - Wagner, Zachary

AU - Montoy, Juan Carlos C.

AU - Drabo, Emmanuel

AU - Dow, William H.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Many HIV positive individuals are still undiagnosed, which has led health systems to try many approaches to expand HIV testing. In a randomized controlled trial, we found that behavioral economics interventions (opt-out testing and financial incentives) each improved HIV testing rates and these approaches are being implemented by several hospital systems. However, it is unclear if these strategies are cost-effective. We quantified the cost-effectiveness of different behavioral approaches to HIV screening—opt-out testing, financial incentives, and their combination—in terms of cost per new HIV diagnosis and infections averted. We estimated the incremental number of new HIV diagnoses and program costs using a mathematical screening model, and infections averted using and HIV transmission model. We used a 1-year time horizon and a hospital perspective. Switching from opt-into opt-out results in 39 additional diagnoses (56% increase) after 1-year at a cost of $3807 per new diagnosis. Switching from no incentive to a $1, $5, or $10 incentive adds 14, 13, and 28 new diagnoses (20, 19, and 41% increases) at a cost of $11,050, $17,984, and $15,298 per new diagnosis, respectively. Layering on financial incentives to opt-out testing enhances program effectiveness, though at a greater marginal cost per diagnosis. We found a similar pattern for infections averted. This is one of the first cost-effectiveness analyses of behavioral economics interventions in public health. Changing the choice architecture from opt-into opt-out and giving financial incentives for testing are both cost-effective in terms of detecting HIV and reducing transmission. For hospitals interested in increasing HIV screening rates, changing the choice architecture is an efficient strategy and more efficient than incentives.

AB - Many HIV positive individuals are still undiagnosed, which has led health systems to try many approaches to expand HIV testing. In a randomized controlled trial, we found that behavioral economics interventions (opt-out testing and financial incentives) each improved HIV testing rates and these approaches are being implemented by several hospital systems. However, it is unclear if these strategies are cost-effective. We quantified the cost-effectiveness of different behavioral approaches to HIV screening—opt-out testing, financial incentives, and their combination—in terms of cost per new HIV diagnosis and infections averted. We estimated the incremental number of new HIV diagnoses and program costs using a mathematical screening model, and infections averted using and HIV transmission model. We used a 1-year time horizon and a hospital perspective. Switching from opt-into opt-out results in 39 additional diagnoses (56% increase) after 1-year at a cost of $3807 per new diagnosis. Switching from no incentive to a $1, $5, or $10 incentive adds 14, 13, and 28 new diagnoses (20, 19, and 41% increases) at a cost of $11,050, $17,984, and $15,298 per new diagnosis, respectively. Layering on financial incentives to opt-out testing enhances program effectiveness, though at a greater marginal cost per diagnosis. We found a similar pattern for infections averted. This is one of the first cost-effectiveness analyses of behavioral economics interventions in public health. Changing the choice architecture from opt-into opt-out and giving financial incentives for testing are both cost-effective in terms of detecting HIV and reducing transmission. For hospitals interested in increasing HIV screening rates, changing the choice architecture is an efficient strategy and more efficient than incentives.

KW - Behavioral economics

KW - Cost-effectiveness

KW - Defaults

KW - HIV testing

KW - Incentives

UR - http://www.scopus.com/inward/record.url?scp=85064260369&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064260369&partnerID=8YFLogxK

U2 - 10.1007/s10461-019-02425-8

DO - 10.1007/s10461-019-02425-8

M3 - Article

C2 - 30953306

AN - SCOPUS:85064260369

JO - AIDS and Behavior

JF - AIDS and Behavior

SN - 1090-7165

ER -